2024年5月31日~6月4日に米国シカゴとオンラインのハイブリッドで開催される、米国臨床腫瘍学会年次集会(2024 Annual Meeting of the American Society of Clinical Oncology®)より、大腸癌、食道癌、膵癌などの消化器癌の注目演題のレポートをお届けします。臨床研究の第一線で活躍するドクターにより執筆、監修されたレポートを楽しみにしてください。

更新履歴

Live Short Cuts

演題レポート

Colorectal Cancer

Oral Abstract #LBA3502
大腸癌

Primary Endpoint Analysis of the ORCHESTRA TRIAL: A randomized phase III trial of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer

Elske C. Gootjes, et al.

Oral Abstract #3500
大腸癌

Liver Transplantation and Chemotherapy versus Chemotherapy alone in patients with definitively unresectable colorectal liver metastases: results from a prospective, multicentre, randomized trial (TransMet)

René Adam, et al.

Oral Abstract #3503
大腸癌

Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: expanded efficacy analysis from CheckMate 8HW

Heinz-Josef Lenz, et al.

Poster Abstract #3528
大腸癌

Combined amphiregulin and epiregulin expression as a prognostic and predictive biomarker of panitumumab (Pmab), fluorouracil, and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212)

Arndt Stahler, et al.

Non-Colorectal Cancer

Oral Abstract #4000
食道胃接合部癌
食道癌

A phase II/III study of peri-operative nivolumab and ipilimumab in patients with locoregional esophageal and gastroesophageal junction adenocarcinoma-results of the neoadjuvant pathologic complete response (pCR) rate: ECOG-ACRIN EA2174

Jennifer R. Eads, et al.

Poster Abstract #4036
食道胃接合部癌
胃癌

Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line treatment for patients with claudin 18 isoform 2 (CLDN18.2)+, HER2-, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Kohei Shitara, et al.